Skip to main content

Table 4 Treatment-related adverse events

From: Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review

Treatment-relate adverse events

Grade 1–2

Grade3

Grade4

Anemia

8 (62%)

0

0

Alanine aminotransferase

Increased

6 (46%)

0

0

Constipation

1 (8%)

0

0

Rash

1 (8%)

0

0

Thrombocytopenia

3 (23%)

0

0

Leukopenia

2 (15%)

1 (8%)

0

Hypoproteinemia

3 (23%)

0

0

Hypokalemia

1 (8%)

0

0

Hyperuricemia

3 (23%)

0

0

Postoperative complications

0

0

1 (8%)